✦ LIBER ✦

Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer

✍ Scribed by Yoshihiro Wada; Ken Kikuchi; Wataru Takahashi; Jiro Honda; Juro Nakanishi; Koichiro Matsumoto; Tomohiro Kuwahara; Nobuyuki Kai; Hiroaki Kikukawa; Shoichi Ueda

Publisher: Springer
Year: 2007
Tongue: English
Weight: 409 KB
Volume: 61
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-007-0445-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intermittent docetaxel therapy with estr

Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

✍ Norihito Soga; Manabu Kato; Kouhei Nishikawa; Yoshihiro Hasegawa; Yasushi Yamada 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 305 KB

Combination chemotherapy with weekly pac

Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer

✍ Tomihiko Yasufuku; Katsumi Shigemura; Osamu Matsumoto; Soichi Arakawa; Masato Fu 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 168 KB

A phase 2 study of carboplatin plus doce

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

The use of flutamide in hormone-refracto

The use of flutamide in hormone-refractory metastatic prostate cancer

✍ D. G. McLeod; R. C. Benson Jr; M. A. Eisenberger; E. D. Crawford; B. A. Blumenst 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

Prostate specific antigen levels and cli

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

✍ James A. Storlie; Jan C. Buckner; Gregory A. Wiseman; Patrick A. Burch; Lynn C. 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi